利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

109 条记录 (耗时 0.023 秒)

    Production of vaccines
    12.
    发明授权
    Production of vaccines 有权
    生产疫苗

    公开(公告)号：US07527961B2

    公开(公告)日：2009-05-05

    申请号：US11271368

    申请日：2005-11-11

    申请人： Maria Grazia Pau ,  Alphonsus G. C. M. UytdeHaag ,  Govert Johan Schouten

    发明人： Maria Grazia Pau ,  Alphonsus G. C. M. UytdeHaag ,  Govert Johan Schouten

    IPC分类号： C12N7/00

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/5252 ,  A61K2039/70 ,  C12N2720/12351 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16234 ,  C12N2770/20051 ,  C12N2770/24051 ,  C12N2770/24151

    摘要： Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.

    摘要翻译： 用于生产哺乳动物病毒的方法和方法，所述方法包括用病毒感染永生化人细胞的培养物，在病毒生长的条件下孵育感染病毒的培养物繁殖病毒，并形成含病毒的培养基， 并除去含病毒的培养基。 可以收获病毒并用于生产疫苗。 优点包括本发明的人细胞可以在规定的无血清条件下进行培养，并且细胞显示出增强的病毒传播能力。 提供了用于在培养的人类细胞中产生流感病毒及其衍生的疫苗的方法。 该方法消除了使用全鸡胚胎生产流感疫苗的必要性。 该方法还提供了连续或间歇地除去培养基。 因此，本发明允许病毒的大规模连续生产达到高滴度。

    Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
    15.
    发明授权
    Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors 失效
    高热和免疫治疗白血病淋巴瘤和实体瘤

    公开(公告)号：US06524587B1

    公开(公告)日：2003-02-25

    申请号：US09499050

    申请日：2000-02-04

    申请人： Bruce W. Lyday

    发明人： Bruce W. Lyday

    IPC分类号： A61K3576

    CPC分类号： A61K35/768 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/5154 ,  C12N7/00 ,  C12N2770/24132 ,  C12N2770/24151 ,  Y02A50/386 ,  A61K2300/00

    摘要： An improved method of inducing whole-body hyperthermia and enhanced anti-tumor immune response through inoculation of a fever virus with nil mortality and subsequent injection of irradiated tumor cells derived from the patient. This therapy will safely reduce the tumor burden by 90-99.9% by physical means (fever), before raising interferon levels to over 250 times baseline. The Activated Lymphokine Killer cells produced by these high interferon levels are capable of killing any cell expressing viral or tumor antigens, even those which had previously escaped immune surveillance. As a final step in the process, a specific class of Cytotoxic T Lymphocytes programmed to destroy the patient's own cancer cells will be produced by repeated inoculation of irradiated cancer cells harvested from the patient. Through a combination of three methods of therapy never previously integrated into a single regimen, it is logical to state that this therapy has a high probability of completely eradicating cancer cells from the patient. In addition, this therapy provides for life-long immunity to the reoccurrence of the disease.

    摘要翻译： 通过接种具有死亡率的发热病毒并随后注射来自患者的照射的肿瘤细胞的方法来诱导全身热疗和增强的抗肿瘤免疫应答。 在将干扰素水平提高到基线的250倍以上之前，这种治疗将通过物理手段（发烧）将肿瘤负担安全地降低90-99.9％。 由这些高干扰素水平产生的活化淋巴因子杀伤细胞能够杀死任何表达病毒或肿瘤抗原的细胞，甚至能够先前逃避免疫监视的细胞。 作为该过程的最后一步，将通过重复接种从患者收获的照射的癌细胞来产生程序化以破坏患者自己的癌细胞的特定类别的细胞毒性T淋巴细胞。 通过将三种先前并入单一方案的治疗方法结合起来，合乎逻辑地说，该疗法具有从患者中完全根除癌细胞的高概率。 此外，这种治疗方法可以为疾病的复发提供终身免疫力。

    Industrial production process for a vaccine against Japanese encephalitis virus and vaccine produced
    16.
    发明授权
    Industrial production process for a vaccine against Japanese encephalitis virus and vaccine produced 有权
    用于针对日本脑炎病毒和疫苗生产的疫苗的工业生产过程

    公开(公告)号：US06149917A

    公开(公告)日：2000-11-21

    申请号：US263

    申请日：1998-08-13

    申请人： Bernard Fanget ,  Alain Francon ,  Pierre Heimendinger

    发明人： Bernard Fanget ,  Alain Francon ,  Pierre Heimendinger

    IPC分类号： A61K35/74 ,  A61K39/00 ,  A61K39/12 ,  C12N7/02 ,  C12N7/06

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  C12N2770/24134 ,  C12N2770/24151

    摘要： A method is disclosed for industrially producing a Japanese encephalitis vaccine, wherein (a) cells from a cell line are cultured, (b) the resulting cell culture is inoculated with a Japanese encephalitis virus in the presence of a viral growth medium, (c) the virus is propagated and multiplied on the cells, (d) the viral growth medium is recovered in the form of a suspension of viruses produced by the cells, (e) the virus suspension is purified in at least one ion exchange chromatography step and a gel permeation step, and (f) the virus suspension is formulated and converted into a pharmaceutical form to preserve it until the moment of use. A Japanese encephalitis vaccine characterised in that it comprises a Japanese encephalitis virus produced by culturing cells from a cell line, and in that the cellular DNA content is less than 100 pg/dose, is also disclosed.

    摘要翻译： PCT No.PCT / FR96 / 01195 Sec。 371日期1998年8月13日 102（e）1998年8月13日PCT PCT 1996年7月29日PCT公布。 出版物WO97 / 04803 日本1997年2月13日公开了用于工业生产日本脑炎疫苗的方法，其中（a）培养来自细胞系的细胞，（b）在病毒生长的存在下将所得细胞培养物接种于日本脑炎病毒 培养基，（c）病毒在细胞上繁殖繁殖，（d）以细胞产生的病毒悬浮液的形式回收病毒生长培养基，（e）将病毒悬浮液在至少一种离子 交换色谱步骤和凝胶渗透步骤，和（f）将病毒悬浮液配制并转化成药物形式以保存直到使用时刻。 日本脑炎疫苗的特征在于，其包含通过从细胞系培养细胞产生的日本脑炎病毒，并且细胞DNA含量小于100pg /剂量。

    Hyperthermia and immunotherapy for cancer
    17.
    发明授权
    Hyperthermia and immunotherapy for cancer 失效
    癌症的热疗和免疫治疗

    公开(公告)号：US6048686A

    公开(公告)日：2000-04-11

    申请号：US73322

    申请日：1998-05-05

    申请人： Bruce William Lyday

    发明人： Bruce William Lyday

    IPC分类号： A61K35/12 ,  A61K35/76 ,  C12N7/02 ,  C12Q1/70 ,  A61K39/193

    CPC分类号： C12N7/00 ,  A61K35/76 ,  C12N2770/24132 ,  C12N2770/24151

    摘要： An improved method of inducing whole-body hyperthermia and enhanced anti-tumor immune response through inoculation of a fever virus with nil mortality and subsequent injection of irradiated tumor cells derived from the patient. This therapy will safely reduce the tumor burden by 90-99.9% by physical means (fever), before raising interferon levels to over 250 times baseline. The Activated Lymphokine Killer cells produced by these high interferon levels are capable of killing any cell expressing viral or tumor antigens, even those which had previously escaped immune surveillance. As a final step in the process, a specific class of Cytotoxic T Lymphocytes programmed to destroy the patient's own cancer cells will be produced by repeated inoculation of irradiated cancer cells harvested from the patient. Through a combination of three methods of therapy never previously integrated into a single regimen, it is logical to state that this therapy has a high probability of completely eradicating cancer cells from the patient. In addition, this therapy provides for life-long immunity to the reoccurrence of the disease. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various changes or modifications in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

    摘要翻译： 通过接种具有死亡率的发热病毒并随后注射来自患者的照射的肿瘤细胞的方法来诱导全身热疗和增强的抗肿瘤免疫应答。 在将干扰素水平提高到基线的250倍以上之前，这种治疗将通过物理手段（发烧）将肿瘤负担安全地降低90-99.9％。 由这些高干扰素水平产生的活化淋巴因子杀伤细胞能够杀死任何表达病毒或肿瘤抗原的细胞，甚至能够先前逃避免疫监视的细胞。 作为该过程的最后一步，将通过重复接种从患者收获的照射的癌细胞来产生程序化以破坏患者自己的癌细胞的特定类别的细胞毒性T淋巴细胞。 通过将三种先前并入单一方案的治疗方法结合起来，合乎逻辑地说，该疗法具有从患者中完全根除癌细胞的高概率。 此外，这种治疗方法可以为疾病的复发提供终身免疫力。 应当理解，本文描述的示例和实施例仅用于说明目的，并且将对本领域技术人员提出对其的各种改变或修改，并且将被包括在本申请的精神和范围内， 所附权利要求。